Table 1

Characteristics of the trials included in the meta-analysis

Study	Pioneer-AF-PCI			Re-dual PCI
Subgroup	Rivaroxaban 15 mg+DAPT	Standard triple therapy	Rivaroxaban 2.5 mg+DAPT	Dabigatran 150 mg+P2Y₁₂	Standard triple therapy	Dabigatran 110 mg+P2Y₁₂
N total bleeding (%)	16.8	26.7	18	33.3	42.9/41.4*	27.1
N MACE (%)	6.5	5.6	6	11.8	13.4/12.8*	15.2
Total bleeding HR (DOAC regimen vs VKAs regimen)†	0.59 (CI 0.47 to 0.76)		0.63 (CI 0.50 to 0.80)	0.72 (CI 0.61 to 0.84)		0.54 (CI 0.46 to 0.63)
P value	<0.001		<0.001	<0.001		<0.001
MACE HR (DOAC regimen vs VKAs regimen)†	1.08 (CI 0.69 to 1.68)		0.93 (CI 0.59 to 1.48)	0.89 (CI 0.67 to 1.14)		1.13 (CI 0.90 to 1.43)
P value	0.75		0.76	0.44		0.30

Cumulative incidence of one primary safety and one secondary efficacy endpoint calculated in the two trials. HRS are intended with 95% CI.
*The two values refer to the number of patients used for HR in dabigatran 150/dabigatran 110 mg arms.
†HRs are calculated from comparison of single subgroups couples (ie, rivaroxaban 15 mg+DAPT vs standard triple therapy).
AF, atrial fibrillation; DAPT, double antiplatelet therapy; DOAC, advent of direct oral anticoagulants; MACE, major cardiovascular events; PCI, percutaneous coronary interventions; VKAs, vitamin K antagonists.